Article

Heteroaryl-Ethylenes as New Effective Agents for High Priority Gram-Positive and Gram-Negative Bacterial Clinical Isolates

Dalida Angela Bivona [1][†]**, Alessia Mirabile**[1][†]**, Carmelo Bonomo**[1]**, Paolo Giuseppe Bonacci**[1]**, Stefano Stracquadanio**[1]**, Andrea Marino**[1]**, Floriana Campanile**[1]**, Carmela Bonaccorso**[2]**, Cosimo Gianluca Fortuna**[2]**, Stefania Stefani**[1]**, Nicolò Musso**[1] **and Dafne Bongiorno**[1]***.**

[1]Section of Microbiology, Department of Biomedical and Biotechnological Sciences (BIMETEC), University of Catania, 95123 Catania, Italy; dalidabivona@gmail.com (DAB); alessiamirabile93@gmail.com (AM); carmelo.bonomo@phd.unict.it (CB); paolo.bonacci@unict.it (PGB); stefano.stracquadanio@unict.it (SStr); andreamarino9103@gmail.com (AM); f.campanile@unict.it (FC); stefania.stefani@unict.it (SS); nmusso@unict.it (NM); dafne.bongiorno@unict.it (DB)

[2]Department of Chemical Sciences, University of Catania, 95125 Catania, Italy. bonaccorsoc@gmail.com (CaB); cg.fortuna@unict.it (CGF);

[†] both aa contributed equally to the manuscript
* Correspondence: dafne.bongiorno@unict.it (DB)

Abstract: The World Health Organization has identified antimicrobial resistance as a public health emergency and developed a global priority pathogens list of antibiotic-resistant bacteria that can be summarized in the acronym ESKAPE (*Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa* and *Enterobacterales* species), reminding us of their ability to escape the effect of antibacterial drugs. We previously tested new heteroaryl-ethylene compounds in order to define their spectrum of activity and antibacterial capability. Now, we focus our attention on PB4, a compound with promising MIC and MBC values in all conditions tested. In the present study, we evaluate the activity of PB4 on selected samples of ESKAPE isolates from nosocomial infections: 14 *S. aureus*, 6 *E. faecalis*, 7 *E. faecium*, 12 *E. coli* and 14 *A. baumanii*. Furthermore, an ATCC control strain was selected for all species tested. MICs were performed according to the standard method, with some modifications. PB4 MIC values were within very low ranges regardless of bacterial species and resistance profiles: from 0,12 to 2 mg/L for *S. aureus*, *E. faecalis*, *E. faecium* and *A. baumannii*. For *E. coli*, the MIC values obtained were slightly higher (4-64 mg/L), butstill promising. The PB4 heteroaryl-ethylenic compound was able to counteract the bacterial growth of both high-priority Gram-positive and Gram-negative clinical strains. In the future, it would be interesting to evaluate the activity of PB4 in animal models to test for its toxicity.

Keywords: ESKAPE; heteroaryl-ethylenes; clinical strains; antimicrobial activity

1. Introduction

An important result of modern medicine was the efficient treatment of bacterial infections with antibiotics but, over the years, bacteria have found a way to resist the action of antimicrobial drugs. [1]

Antimicrobial resistance (AMR) is a crucial global concern due to the increased and irresponsible use of antibiotics promoting the selection and spread of antibiotic-resistant pathogens responsible for difficult-to-treat infections, especially in Intensive Care Units (ICUs).

Infections caused by multi-drug resistant (MDR) pathogens can lead to additional complications such as prolonged hospital stays and prolonged treatment with last-line antibiotics, which enhance the selection of resistant microbiota, associated to higher healthcare costs. Bacterial resistance can be both intrinsic and acquired, the latter possibly being greatly enhanced by antimicrobial drugs exposure. [2]

In 2017, the World Health Organization (WHO) worked out an acronym, ESKAPE, to cover the *Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,* and *Enterobacterales* species [3]; to date, we are still facing a worldwide prevalence of MDR pathogens.

Gram-positive bacteria (GPB) have developed particular resistant profiles, such as Methicillin-Resistant *Staphylococcus aureus* (MRSA) [4] or Vancomycin-Resistant enterococci (VRE) [5] and are often related to nosocomial infections. Both these pathogens are responsible for enhanced morbidity and mortality due to the ineffectiveness of "last resort" antibiotics. [6]

MRSA strains are characterized by a mobile genetic element carrying the methicillin-resistance gene (*mec*A), called Staphylococcal Chromosomal Cassette (SCC*mec*), usually type I, II or III. [7][8] Clinically, the acquisition of resistance to multiple antibiotic classes by *S. aureus* complicates treatment. [9] *E. faecalis* and *E. faecium* are responsible for the majority of human infections and related to the presence of bladder catheter, and/or neutropenia. [11] Nosocomial infections with enterococci are often associated with peculiar antimicrobial resistant profiles exhibiting a high level of intrinsic resistance to penicillins, cephalosporins, aminoglycosides and carbapenems. [12] As shown above, the WHO list mainly consists of Gram-negative bacteria (GNB). *Enterobacterales* resistance to third generation cephalosporins and carbapenems is increasing worldwide and is now above 10% and 2-7%, respectively. [2] This is due to the spread of Extended Spectrum Beta-Lactamases (ESBLs) (CTX-M, TEM, SHV) and carbapenemases (VIM, IMP, NDM, KPC and OXA). [13]

E. coli and *K. pneumoniae* are ESBL producers; compared to non-ESBLs, they express more TEM1, TEM2 and SHV capable of hydrolyzing narrow spectrum cephalosporins, carbapenems and monobactams. The administration of piperacillin/tazobactam, a treatment that alternates a β-lactam and β-lactamase inhibitor, has been considered as a carbapenem-sparing regimen for ESBL infections, although the global trend of AmpC β-lactamase-producing bacteria should be carefully monitored. [15] *A. baumannii* is one of the most successful pathogens in causing nosocomial infections, and carbapenem-resistant *A. baumannii* (CRAB) is often isolated in hospital settings. Current antimicrobials for CRAB (i.e., polymyxins, tigecycline, and sometimes aminoglycosides) are far from being perfect therapeutic options due to their pharmacokinetic properties and increasing resistance rates. [16]

In such a critical situation, the introduction in the clinical practice of new molecules able to counteract the continuous increase of multidrug-resistant pathogens is unquestionably a current priority. In fact, while the constant introduction of new drugs has long allowed to bypass the issue of antibiotic resistance, the current lack of molecules effective against MDR pathogens is becoming of growing concern.

In a previous study by Bongiorno *et al*, the spectrum of ability of eight heteroaryl-ethylene compounds, called PBn, as antimicrobial agents capable of inhibiting the proliferation of a selected sample of Gram-positive and Gram-negative ATCC strains was tested by MIC (minimal inhibition concentration) and MBC (minimal bactericidal concentration) assays. Furthermore, the presence of an inoculum effect was assessed at scalar inoculum concentrations, and the cytotoxicity of the new molecules on colorectal adenocarcinoma cancer cells (CaCo2) was analyzed. [17] Our preliminary results were highly encouraging and pave the way for further investigations of heteroaryl-ethylenes as antimicrobial agents in the treatment of several Gram-positive and Gram-negative bacterial infections, especially those caused by MRSA, VRE, ESBL and *A. baumannii*.

In the present study, we have focused our attention on PB4, a compound with low MIC and MBC values in all conditions tested. PB4 activity was evaluated on a selected sample of MRSA, VRE, ESBL and CRAB freshly isolated from nosocomial infections.

2. Results

In this study, we selected Gram-positive and Gram-negative clinical strains with different antibiotic resistance profiles, including 14 *S. aureus*, 6 *E. faecalis*, 7 *E. faecium*, 14 *A. baumannii*, 12 *E. coli*, with the aim to understand the potency and antimicrobial capacity of PB4. Furthermore, an ATCC control strain was selected for all species tested.

2.1 Gram-positive clinical strains

PB4 was tested against both MRSA and MSSA isolates (11 and 3 strains, respectively). PB4 showed an antimicrobial activity of 0,25 mg/L MIC on *S. aureus* ATCC29213. The MIC values of PB4 were within a range of 0,12 mg/L to 0,5 mg/L for all *S. aureus* strains tested. PB4 was active on 3 MSSA and 8 MRSA at a concentration of 0,12 mg/L, proving effective at very low concentrations despite the greater aggressiveness of the control MRSA strains included in the study. Slightly higher concentrations of PB4 (0,25 mg/L and 0,5 mg/L) were enough to inhibit the growth of the 3 remaining clinical MRSA strains (see Table 1).

Antimicrobial resistant profile	Strain	MIC (mg/L) PB4
	S. aureus ATCC 29213	0,25
MSSA	1-CT	0,12
MSSA	2-CT	0,12
MSSA	3-CT	0,12
MRSA	4-CT	0,12
MRSA	5-CT	0,12
MRSA	6-CT	0,12
MRSA	7-CT	0,12
MRSA	8-CT	0,12
MRSA	9-CT	0,12
MRSA	10-CT	0,12
MRSA	11-CT	0,12
MRSA	12-CT	0,25
MRSA	13-CT	0,5
MRSA	14-CT	0,5

Table 1: Activity of PB4 on *S. aureus* ATCC 29213 control strain and on 14 clinical *S. aureus* strains (3 MSSA and 11 MRSA).

Enterococcus spp clinical strains were selected for different antibiotic resistance profiles, including 6 *E. faecalis* (VRE, MDR, Not MDR) and 7 *E. faecium* (VRE, Linezolid Resistant (LinR), MDR, Not MDR). *E. faecalis* ATCC 29212 and ATCC 51299, with a PB4 MIC value of 0,5 mg/L, were included. The MIC values for PB4 were comprised in a range between 0,12 mg/L and 2 mg/L when tested on Enterococci.

In particular, PB4, independently of their antibiotic profile, showed a MIC range of 0,25 to 0,5 mg/L for *E. faecalis* strains, and of 0,12 to 2mg/L for *E. faecium.*

The MIC values for PB4 in the *Enterococcus* spp. sample are reported in Table 2.

	Antimicrobial resistance profile		MIC (mg/L)
		Strain	**PB4**
		E. faecalis ATCC 29212	0,5
		E. faecalis ATCC 51299	0,5
Enterococcus faecalis	**VRE**	15-CT	0,25
		16-CT	0,25
		17-CT	0,5
	MDR	18-CT	0,25
	NOT MDR	19-CT	0,25
		20-CT	0,5
Enterococcus faecium	**VRE**	21-CT	0,25
		22-CT	1
	Lin R	23-CT	0,5
		24-CT	1
	MDR	25-CT	0,12
		26-CT	1
	NOT MDR	27-CT	2

Table 2: Activity of PB4 on *E. faecalis* ATCC 29212 and *E. faecalis* ATCC 51299 control strains, on 6 *E. faecalis* and on 7 *E. faecium* clinical strains (VRE, LinR, MDR, not MDR).

2.3 Gram-negative clinical strains

Furthermore, 12 clinical strains were selected for their different antibiotic resistance profiles, in particular 3 ESBL and 9 non-ESBL *E. coli*.

E. coli ATCC 25922 was chosen as control strain in order to test the activity of PB4 on this species, and the compound showed a MIC value of 1 mg/L. The MIC values for PB4 were comprised in a range between 4 mg/L and 64 mg/L. The MIC values for PB4 were heterogeneous on *E. coli*, showing different behaviors for the three different ESBL clinical strains. Regarding non-ESBL *E. coli*, PB4 MIC values of 4 mg/L were obtained for 5 clinical strains, 8 mg/L for 1 clinical strain, and 32 mg/L for the 2 remaining clinical strains (see Table 3).

MIC (mg/L)

Antimicrobial resistance profile	Strain	PB4
	E. coli ATCC 25922	1
ESBL	28-CT	4
	29-CT	16
	30-CT	64
susceptible	31-CT	4
	32-CT	4
	33-CT	4
	34-CT	4
	35-CT	4
	36-CT	8
	37-CT	32
	38-CT	32
	39-CT	64

Table 3: Activity of PB4 on *E. coli* ATCC 25922 control strain and on 12 *E. coli* clinical strains (ESBL and susceptible).

Regarding clinical strains, we selected 14 clinical MDR strains with particular attention to their carbapenem-resistance profiles – Carbapenem Resistant *A. baumannii* (CRAB) - and obtained PB4 MIC values comprised in a range between <0,12 mg/L and 1 mg/L (see Table 4). A previous observation showed that PB4 may be active on *A. baumannii* ATCC 17978 control strain, with an antimicrobial activity of 0,5 mg/L MIC.

Antimicrobial resistance profile		MIC (mg/L)
	Strain	PB4
	A. baumannii ATCC 17978	0,5
CRAB	40-CT	<0,12
	41-CT	<0,12
	42-CT	<0,12
	43-CT	<0,12
	44-CT	0,25
	45-CT	0,25
	46-CT	0,25
	47-CT	0,25
	48-CT	0,25
	49-CT	0,25
	50-CT	0,5
	51-CT	0,5
	52-CT	0,5
	53-CT	1

Table 4: Activity of PB4 on *A. baumanii* ATCC 17978 control strain and 14 CRAB clinical strains

A summary table (see Table 5) of the results obtained was added to clarify the activity of PB4. The PB4 MIC values obtained on the control strains are reported on the far left of the table as a reference.
In general, we have seen that PB4 is effective at very low ranges, and this is true for all Gram-positive and Gram-negative clinical strains tested regardless of the species and their particular antibiotic resistance profile.

On *S. aureus* clinical strains, PB4 showed an inhibitory efficacy in a range comprised between 0,12 and 0,5 mg/L; **11**/14 clinical strains exhibited the lowest MIC value recorded of 0,12 mg/L, **1**/14 of 0,25 mg/L, and **2**/14 of 0,5 mg/L; for *S. aureus* ATCC 29213, a PB4 MIC value of 0,25 mg/L was collected.

On *E. faecalis* clinical strains, PB4 was effective in a range comprised between 0,25 and 0,5 mg/L; **4**/6 clinical strains exhibited the lowest MIC value recorded of 0,25 mg/L, **2**/6 of 0,5 mg/L.
On *E. faecium* clinical strains, PB4 activity was detected in a range comprised between 0,12 and 2 mg/L, **3**/7 clinical strains had low MIC values in a range of 0,12 to 0,25-0,5 mg/L; **3**/7 showed an intermediate MIC value of 1 mg/L, while the last clinical strain exhibited the highest MIC value of 2 mg/L. For *E. faecalis* ATCC 29212 and *E. faecalis* ATCC 51299, a PB4 MIC value of 0,5 mg/L was collected.

On *E. coli* clinical strains, PB4 efficacy was assessed in a range comprised between 4 and 64 mg/L; **6**/12 clinical strains exhibited the lowest MIC value of 4 mg/L, **1**/12 of 8 mg/L, **1**/12 of 16 mg/L, **2**/12 of 32 mg/L, and only **2**/12 strains had the highest MIC value of 64 mg/L. For *E. coli* ATCC 25922, a PB4 MIC value of 1 mg/L was collected.

On *A. baumannii* clinical strains, PB4 inhibition activity ranged between ≤0,12 and 1 mg/L; **4**/14 clinical strains hadthe lowest MIC value of less than or equal to 0,12 mg/L, **6**/14 of 0,25 mg/L, **3**/14 of 0,5 mg/L, and 1/14 of 1 mg/L. For *A. baumanii* ATCC 17978, a PB4 MIC value of 0,5 mg/L was collected.

Control strain		Species	n.	range	PB4 MIC value (mg/L)										
					128	64	32	16	8	4	2	1	0,5	0,25	0,12
S. aureus ATCC 29213	0,25	*S. aureus*	14	0,12 – 0,5	0	0	0	0	0	0	0	0	2	1	11
E. faecalis ATCC 29212	0,5	*E. faecalis*	6	0,25 – 0,5	0	0	0	0	0	0	0	0	2	4	0
E. faecalis ATCC 51299 VRE	0,5	*E. faecium*	7	0,12 – 2	0	0	0	0	0	0	1	3	1	1	1
E. coli ATCC 25922	1	*E. coli*	12	4 – 64	0	2	2	1	1	6	0	0	0	0	0
A. baumannii ATCC 17978	0,5	*A. baumanii*	14	≤0,12 – 1	0	0	0	0	0	0	0	1	3	6	4

Table 5: On the left are reported the MIC values of PB4 on the control strains used as references. The number of clinical strains tested for each species, the PB4 MIC ranges obtained and the distribution of the results are shown alongside.

3. Discussion

In 2017, the World Health Organization (WHO) published a list of antibiotic-resistant priority pathogens that can be summarized in the acronym ESKAPE (*E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa* and *Enterobacter* spp), reminding us of their ability to escape the effect of antibacterial drugs, which, in turn, accounts for their ability to cause serious, difficult-to-control Gram-positive and Gram-negative bacterial infections, especially in the hospital setting.

Thus, we focused our attention on *S. aureus* (MSSA and MRSA), VR and LinR *E. faecalis* and *E. faecium*, ESBL *E. coli*, carbapenem resistant *A. baumannii* (CRAB). For this purpose, in a previous study we had tested newly synthesized molecules derived from the condensation of heterocyclic aromatic aldehydes: the PB compounds. These eight molecules were tested on Gram-positive and Gram-negative ATCC control strains to characterize their antimicrobial activity, determining their MIC and MCB values. [17]

Based on previous results, PB4 was selected as the compound candidate to be tested on MSSA and MRSA, VRE and LinR *Enterococci*, ESBL *E. coli*, and CRAB.
Surprisingly, despite the antimicrobial resistance profile which characterizes every single clinical strain, PB4 showed a good level of activity. Indeed, the MIC values of PB4 were within very low ranges regardless of bacterial species and resistance profiles: from 0,12 to 0,5 mg/L for both MSSA and MRSA; from 0,25 to 0,5 mg/L for *E. faecalis* and from 0,12 to 2 mg/L for *E. faecium*.
Only for *E. coli*, including the ATCC strain, which showed a MIC value of 1 mg/L, the MIC values obtained were from 4 mg/L to 64 mg/L, slightly higher than for other microorganisms tested but still promising.
Remarkably, for *A. baumannii* clinical strains, the inhibitory activity of PB4 ranged from ≤0,12 mg/L to 1 mg/L, despite their being MDR and, especially, their resistance to carbapenems (CRAB)

In this study, we observed that PB4, a heteroaryl-ethylenic compound, can counteract the bacterial growth of both high-priority Gram-positive and Gram-negative clinical strains. Our aim was to contribute to the search for new molecules that can fight bacterial infections, in particular those caused by MDR bacteria in hospitals, where serious infections, combined with impaired pathophysiology and immunity of patients, cannot but worsen their clinical picture and outcome.
In the future, in order to better investigate the good antimicrobial capability found in bacterial strains through *in vitro* studies and in prokaryotic cells, it would be interesting to test PB4 for its toxicity and antimicrobial activity using *in vivo* models.
This is a crucial aspect, because the molecule could fail *in vivo* depending on its toxicity or rate of elimination by the organism to which it is administered.

4. Materials and Methods

4.1 Microorganisms and growth conditions

Control strains of Gram-positive and Gram-negative bacteria, *E. faecalis* ATCC 29212 VSE, *E. faecalis* ATCC 51299 VRE, *S. aureus* ATCC 29213, *E. coli* ATCC 25922, *A. baumannii* ATCC 17978, were obtained from the American Type Culture Collection (Manassas, VA).

In this study, fourteen *S. aureus*, six *E. faecalis*, seven *E. faecium* and fourteen *A. baumannii* clinical strains were selected for their resistance profile among the bacterial culture collections of the Medical Molecular Microbiology and Antibiotic Resistance Laboratory (MMARL) of the University of Catania.

Twelve *E. coli* clinical strains were provided by the Laboratory of Microbiology and Clinical Virology - Gaspare Rodolico Hospital of Catania - Vittorio Emanuele University Hospital.

S. aureus was grown on Mannitol Salt Agar (CM0085B, Thermo Scientific™ Oxoid™, Basingstoke, UK), *E. faecalis* on Bile Aesculin Agar (CM0888, Thermo Scientific™ Oxoid™, Basingstoke, UK), *A. baumannii* and *E. coli* on MacConkey Agar (CM0007, Thermo Scientific™ Oxoid™, Basingstoke, UK) at 37 °C for 24 h.

4.2 Minimum inhibitory concentration (MIC)

Microtiter plate assays were performed to determine the minimum inhibitory concentration of PB4 according to the standard method [18], with some modifications.

The PB4 compound was at a concentration of 8000 mg/L in 100% DMSO (85190, Thermo Scientific™ Oxoid™, Basingstoke, UK). Further dilutions of the substance were prepared using Mueller Hinton II Broth [Cation-Adjusted] (CA-MHB) (212322, BD BBLTM, Franklin Lakes, NJ, USA).

The concentration range tested was between 128 mg/L and 0,25 mg/L. A 100 µL aliquot of PB4 was inoculated in 96-well microplates containing sterile CA-MHB, and serial dilutions were performed.

Subsequently, starting from different 0,5 McFarland (10^8 CFU/mL) bacterial suspensions, scalar dilutions of the inoculum were carried out and a concentration of 10^5 CFU/mL was inoculated in 96-well microplates. The microplates were incubated for 18 ± 2 hours at 37 °C. MIC values were determined at the lowest concentrations of the antimicrobial agent inhibiting bacterial growth. The MIC values were expressed in mg/L. The tests were repeated in duplicate.

References

[1]   E. Mühlberg, F. Umstätter, C. Kleist, C. Domhan, W. Mier, and P. Uhl, "Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria.," *Canadian journal of microbiology*, vol. 66, no. 1, pp. 11–16, Jan. 2020, doi: 10.1139/cjm-2019-0309.

[2]   J. L. Martinez, "General principles of antibiotic resistance in bacteria.," *Drug discovery today. Technologies*, vol. 11, pp. 33–9, Mar. 2014, doi: 10.1016/j.ddtec.2014.02.001.

[3]   R. Karaman, B. Jubeh, and Z. Breijyeh, "Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches.," *Molecules (Basel, Switzerland)*, vol. 25, no. 12, Jun. 2020, doi: 10.3390/molecules25122888.

[4]   C. Goll, P. Balmer, F. Schwab, H. Rüden, and T. Eckmanns, "Different trends of MRSA and VRE in a German hospital, 1999-2005.," *Infection*, vol. 35, no. 4, pp. 245–9, Jun. 2007, doi: 10.1007/s15010-007-6234-5.

[5]   M. M. Huycke, D. F. Sahm, and M. S. Gilmore, "Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future.," *Emerging infectious diseases*, vol. 4, no. 2, pp. 239–49, doi: 10.3201/eid0402.980211.

[6]   Z. Wang, B. Cao, Y. Liu, L. Gu, and C. Wang, "Investigation of the prevalence of patients co-colonized or infected with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in China: a hospital-based study.," *Chinese medical journal*, vol. 122, no. 11, pp. 1283–8, Jun. 2009.

[7]   R. H. Deurenberg, C. Vink, S. Kalenic, A. W. Friedrich, C. A. Bruggeman, and E. E. Stobberingh, "The molecular evolution of methicillin-resistant Staphylococcus aureus.," *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*, vol. 13, no. 3, pp. 222–35, Mar. 2007, doi: 10.1111/j.1469-0691.2006.01573.x.

[8]   R. H. Schulte and E. Munson, "Staphylococcus aureus Resistance Patterns in Wisconsin: 2018 Surveillance of Wisconsin Organisms for Trends in Antimicrobial Resistance and Epidemiology (SWOTARE) Program Report.," *Clinical medicine & research*, vol. 17, no. 3–4, pp. 72–81, 2019, doi: 10.3121/cmr.2019.1503.

[9]   W. M. Kirby, "EXTRACTION OF A HIGHLY POTENT PENICILLIN INACTIVATOR FROM PENICILLIN RESISTANT STAPHYLOCOCCI.," *Science (New York, N.Y.)*, vol. 99, no. 2579, pp. 452–3, Jun. 1944, doi: 10.1126/science.99.2579.452.

[10]   K. Reyes, A. C. Bardossy, and M. Zervos, "Vancomycin-Resistant Enterococci: Epidemiology, Infection Prevention, and Control.," *Infectious disease clinics of North America*, vol. 30, no. 4, pp. 953–965, 2016, doi: 10.1016/j.idc.2016.07.009.

[11]   G. Werner *et al.*, "Thirty years of VRE in Germany - 'expect the unexpected': The view from the National Reference Centre for Staphylococci and Enterococci.," *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*, vol. 53, p. 100732, 2020, doi: 10.1016/j.drup.2020.100732.

[12]   W. R. Miller, B. E. Murray, L. B. Rice, and C. A. Arias, "Resistance in Vancomycin-Resistant Enterococci." *Infectious disease clinics of North America*, vol. 34, no. 4, pp. 751–771, 2020, doi: 10.1016/j.idc.2020.08.004.

[13]   C. A. Moxon and S. Paulus, "Beta-lactamases in Enterobacteriaceae infections in children.," *The Journal of infection*, vol. 72 Suppl, pp. S41-9, 2016, doi: 10.1016/j.jinf.2016.04.021.

[14]   "European Centre for Disease Prevention and Control. OXA-244-producing Escherichia coli in the European Un-ion/European Economic Area and the UK since 2013, first update – 20 July 2021. ECDC: Stockholm; 2021."

[15]   Y. Chong, S. Shimoda, and N. Shimono, "Current epidemiology, genetic evolution and clinical impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.," *Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases*, vol. 61, pp. 185–188, 2018, doi: 10.1016/j.meegid.2018.04.005.

[16]   E.-T. Piperaki, L. S. Tzouvelekis, V. Miriagou, and G. L. Daikos, "Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment.," *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*, vol. 25, no. 8, pp. 951–957, Aug. 2019, doi: 10.1016/j.cmi.2019.03.014.

[17]   D. Bongiorno *et al.*, "Heteroaryl-Ethylenes as New Lead Compounds in the Fight against High Priority Bacterial Strains.," *Antibiotics (Basel, Switzerland)*, vol. 10, no. 9, Aug. 2021, doi: 10.3390/antibiotics10091034.

[18]   M. P. Weinstein and J. S. Lewis, "The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing: Background, Organization, Functions, and Processes.," *Journal of clinical microbiology*, vol. 58, no. 3, 2020, doi: 10.1128/JCM.01864-19.